Omalizumab in chronic urticaria: A comprehensive review

Objective & Hypothesis:Omalizumab is a humanized monoclonal anti-immunoglobulin E which is originally developed for the treatment of allergic respiratory disorders,but has been approved for the treatment of antihistamine-resistant chronic spontaneous urticaria in 2014.

📊

Key Findings & Data:It has become a game changer inthe treatment of all subtypes of chronic urticaria (CU) even though it has not been yet approved for inducible urticarias.

💡

Conclusion & Impact:Available information about these questionsare tried to be provided in this review.

🔬Design:Review & Systematic Survey

📍Scope:2014 Verileri

⚙️Variables:Domain Parameters

Abstract

Omalizumab is a humanized monoclonal anti-immunoglobulin E which is originally developed for the treatment of allergic respiratory disorders,but has been approved for the treatment of antihistamine-resistant chronic spontaneous urticaria in 2014. It has become a game changer inthe treatment of all subtypes of chronic urticaria (CU) even though it has not been yet approved for inducible urticarias. It is a safe drug withminor adverse events reported in the clinical trials as well as real life studies. The main questions that remain to be answered regarding its usefor CU are the duration of treatment, how to cease the treatment and safety of long-term use. Available information about these questionsare tried to be provided in this review.

Özet

Humanize monoklonal anti-immunoglobulin E antikoru olan omalizumab ilk kez alerjik solunum yolu hastalıklarının tedavisi için geliştirilmiş olup 2014 yılında antihistamin dirençli kronik spontan ürtiker tedavisi için onay almıştır. Henüz indüklenebilir ürtikerin tedavisinde onaylanmamış olmasına rağmen tüm kronik ürtiker (KÜ) alt tiplerinde başarılı bir şekilde uygulanmaktadır. Klinik çalışmalarda ve gerçek yaşam verilerinde bildirilen hafif yan etkiler güvenli bir ilaç olduğunu düşündürmektedir. KÜ’deki kullanımına ait cevaplanmamış sorular kullanım süresi, tedavinin nasıl kesileceği ve uzun dönem yan etkileridir. Bu derlemede bu sorulara ilişkin cevaplar verilmeye çalışılmaktadır.

🔖

Cite This Article

KIZILTAÇ, K., LESLIE, T., GÖNCÜ, E. K. (2022). Omalizumab in chronic urticaria: A comprehensive review. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 52 - Sayı: 4, 112–119. https://ajindex.com/articles/621689

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (7)

Schulman ES: Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001;164:6-11. Xolair.Prescribing information. 2015; Available from: Available at:http:// www.gene.com/download/pdf/xolair_prescribing.pdf. Last accessed September 2016. EMEA. Xolair SmPC 2016; Available from: Available at:http://ec.europa.eu/ transparency/regdoc/rep/3/2014/EN/3-2014-1463-EN-F1-1-ANNEX-1.PDF. Last accessed September 2016]
Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C: The antiinflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115:459-65. Godse KV: Omalizumab in treatment-resistant chronic spontaneous urticaria. Indian J Dermatol 2011;56:444. Iemoli E, Piconi S, Fusi A, Borgonovo L, Borelli M, Trabattoni D: Immunological effects of omalizumab in chronic urticaria: a case report. J Investig Allergol Clin Immunol 2010;20:252-4.
Saavedra MC, Sur S: Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Mol Allergy 2011;9:2. Sánchez-Machín I, Iglesias-Souto J, Franco A, Barrios Y, Gonzalez R, Matheu V: T cell activity in successful treatment of chronic urticaria with omalizumab. Clin Mol Allergy 2011;9:11. Büyüköztürk S, Gelincik A, Demirtürk M, Kocaturk E, Colakoğlu B, Dal M: Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. J Dermatol 2012;39:439-42.
Kaplan A, Ledford D, Ashby M, et al: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101-9.
Maurer M, Rosén K, Hsieh HJ, et al: Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924-35.
Vestergaard C, Toubi E, Maurer M, et al: Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. Eur J Dermatol 2017;27:10-9.
Metz M, Ohanyan T, Church MK, Maurer M: Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014;150:288-90. Erdem T: Omalizumab. Turkiye Klinikleri J Dermatol-Special Topics 2014;7:102-7. Francés L, Leiva-Salinas M, Silvestre J: Omalizumab in the treatment of chronic urticaria. Actas Dermosifiliogr